Company takes second tilt at a PBAC 'Yes'

Fresh from a PBAC rejection, Bayer has wasted no time snapping up the early re-entry pathway to put a re-submission to expand its star performer Kerendia back before the committee in November.

An update to the November Agenda will see Kerendia back on the table for the treatment of adult patients with symptomatic heart failure (New York Heart Association Class II-IV) and a left ventricular ejection fraction (LVEF) of greater than or equal to 40 per cent.

It's the second tilt at reimbursement for the drug which was first listed on the PBS in July 2023 for chronic kidney disease in Type 2 diabetes.

To see the whole article please log in.

Christine Spiteri

Log in with your member email for full access.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Email

Retype password

Not a member? Sign up here